Cargando…

Role of delayed salvage bevacizumab at symptomatic progression of chemorefractory glioblastoma

BACKGROUND: Assess benefit of salvage bevacizumab (BEV) at time of symptomatic progression in patients with refractory glioblastoma (GBM). METHODS: Patients managed with adjuvant long course chemo-radiation therapy for GBM were entered into a prospective database. At chemorefractory symptomatic prog...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cuncannon, Moire, Wong, Matthew, Jayamanne, Dasantha, Guo, Linxin, Cove, Nicola, Wheeler, Helen, Back, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6518639/ https://www.ncbi.nlm.nih.gov/pubmed/31088401 http://dx.doi.org/10.1186/s12885-019-5678-1

Ejemplares similares

The role of large volume re-irradiation with Bevacizumab in chemorefractory high grade glioma
por: Chan, Joseph, et al.
Publicado: (2020)

Optimising Outcomes for Glioblastoma through Subspecialisation in a Regional Cancer Centre
por: Back, Michael, et al.
Publicado: (2018)

Leptomeningeal neuraxis relapse in glioblastoma is an uncommon but not rare event associated with poor outcome
por: Wegener, Eric, et al.
Publicado: (2023)

Bevacizumab plus chemotherapy as salvage treatment in chemorefractory patients with metastatic colorectal cancer
por: Geva, Ravit, et al.
Publicado: (2013)

Predicting patterns of failure in temporal lobe GBMs: possible implications on radiotherapy treatment portals
por: Jayamanne, Dasantha, et al.
Publicado: (2018)

Large tumour volume reduction of IDH-mutated anaplastic glioma involving the insular region following radiotherapy
por: Metz, Gabrielle, et al.
Publicado: (2022)

Volumetric Response of Limited Brain Metastatic Disease to Focal Hypofractionated Radiation Therapy
por: Wijetunga, Asanka R., et al.
Publicado: (2021)

Bevacizumab-based treatment as salvage therapy in patients with recurrent symptomatic brain metastases
por: Berghoff, Anna Sophie, et al.
Publicado: (2020)

Efficacy and safety of trifluridine/tipiracil plus bevacizumab and trifluridine/tipiracil or regorafenib monotherapy for chemorefractory metastatic colorectal cancer: a retrospective study
por: Chida, Keigo, et al.
Publicado: (2021)

RT-01 Treatment results of salvage gamma knife and bevacizumab (AVAgamma therapy) for recurrent glioblastoma
por: Sato, Kenichi, et al.
Publicado: (2020)

A phase 2 study of panitumumab with irinotecan as salvage therapy in chemorefractory KRAS exon 2 wild-type metastatic colorectal cancer patients
por: Elez, Elena, et al.
Publicado: (2019)

Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients
por: Reardon, D A, et al.
Publicado: (2012)

Bevacizumab for glioblastoma
por: Narita, Yoshitaka
Publicado: (2015)

Comparing the Secretomes of Chemorefractory and Chemoresistant Ovarian Cancer Cell Populations
por: Lee, Amy H., et al.
Publicado: (2022)

Safety and efficacy of bevacizumab biosimilar in recurrent/ progressive glioblastoma
por: Kumar, Gunjesh, et al.
Publicado: (2021)

Long-Time Progression-Free Survival with Trabectedin in Chemorefractory Metastatic Leiomyosarcoma of the Retroperitoneum: A Case Report
por: Reichinger, Andreas
Publicado: (2023)

RT-01 TREATMENT RESULTS OF SALVAGE GAMMA KNIFE STEREOTACTIC RADIOSURGERY AND BEVACIZUMAB (AVAGAMMA THERAPY) FOR RECURRENT GLIOBLASTOMA
por: Sato, Kenichi, et al.
Publicado: (2019)

Intensive care unit outcomes in patients with hematological malignancy
por: Rawson, Jarrod Leigh, et al.
Publicado: (2020)

Apatinib for recurrent/progressive glioblastoma multiforme: A salvage option
por: Zhang, Hong-Hong, et al.
Publicado: (2022)

Bevacizumab for the Treatment of Glioblastoma
por: Gil-Gil, Miguel J., et al.
Publicado: (2013)

Bevacizumab in recurrent glioblastoma
por: Martinez, Nina L., et al.
Publicado: (2019)

Anakoinosis: Communicative Reprogramming of Tumor Systems - for Rescuing from Chemorefractory Neoplasia
por: Hart, Christina, et al.
Publicado: (2015)

Profiling molecular regulators of recurrence in chemorefractory triple-negative breast cancers
por: Hancock, Bradley A., et al.
Publicado: (2019)

Readministration of Cancer Drugs in a Patient with Chemorefractory Metastatic Colorectal Cancer
por: Kawagoe, Tetsuro, et al.
Publicado: (2020)

Chemorefractory Gastric Cancer: The Evolving Terrain of Third-Line Therapy and Beyond
por: Alsina, Maria, et al.
Publicado: (2022)

Effectiveness of lomustine and bevacizumab in progressive glioblastoma: a meta-analysis
por: Song, Jie, et al.
Publicado: (2018)

Improving efficiency in the radiation management of multiple brain metastases using a knowledge‐based planning solution for single‐isocentre volumetric modulated arc therapy (VMAT) technique
por: O’Toole, James, et al.
Publicado: (2021)

Efficacy and safety of the third-generation chloroethylnitrosourea fotemustine for the treatment of chemorefractory T-cell lymphomas
por: Corazzelli, Gaetano, et al.
Publicado: (2011)

Gemcitabine plus capecitabine (Gem–Cape) biweekly in chemorefractory metastatic colorectal cancer
por: Jiménez-Fonseca, P., et al.
Publicado: (2014)

Pericardial Effusion during Proton Therapy in a Patient with Chemorefractory Hodgkin Lymphoma
por: Way, Ashley, et al.
Publicado: (2021)

Bevacizumab for the Treatment of Recurrent Glioblastoma
por: Chamberlain, Marc C.
Publicado: (2011)

Validation of the 8(th) edition UICC/AJCC TNM staging system for HPV associated oropharyngeal cancer patients managed with contemporary chemo-radiotherapy
por: van Gysen, Kirsten, et al.
Publicado: (2019)

Reinduction of Bevacizumab in Combination with Pegylated Liposomal Doxorubicin in a Patient with Recurrent Glioblastoma Multiforme Who Progressed on Bevacizumab/Irinotecan
por: Almubarak, Mohammed, et al.
Publicado: (2008)

Erratum to: Gemcitabine plus capecitabine (Gem–Cape) biweekly in chemorefractory metastatic colorectal cancer
por: Jiménez-Fonseca, P., et al.
Publicado: (2014)

Genomic mutations and histopathologic biomarkers in Y(90) radioembolization for chemorefractory colorectal liver metastases
por: Dendy, Meaghan S., et al.
Publicado: (2018)

Role of bevacizumab therapy in the management of glioblastoma
por: Peak, Scott J, et al.
Publicado: (2010)

Bevacizumab for Glioblastoma—A Promising Drug or Not?
por: Nagane, Motoo, et al.
Publicado: (2013)

Bevacizumab for Patients with Recurrent Multifocal Glioblastomas
por: Burger, Michael C., et al.
Publicado: (2017)

Haploidentical γδ T Cells Induce Complete Remission in Chemorefractory B-cell Non-Hodgkin Lymphoma
por: Bold, Anna, et al.
Publicado: (2023)

RETRO-TAS, a Retrospective Observational Study of Trifluridine/Tipiracil in Chemorefractory Metastatic Colorectal Cancer
por: Koumarianou, Anna, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_tutq7j0hqmrv4gvuuujtu8r2pd